As VM is independent of angiogenesis, malignant tumors, such as GBM, which use this mechanism of vascularization, may display therapeutic resistance to antiangiogenic therapies (AAT), especially CXCR2-expressing tumor cells [183]. Here, CXCR2 is linked to neoplasm.